Soligenix (NASDAQ:SNGX) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Soligenix (NASDAQ:SNGX) posted its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05, Zacks reports.

Soligenix Trading Up 0.5%

Shares of Soligenix stock traded up $0.00 during mid-day trading on Friday, reaching $0.34. 115,354 shares of the stock were exchanged, compared to its average volume of 114,082. The firm has a 50-day simple moving average of $0.36 and a 200 day simple moving average of $0.67. Soligenix has a fifty-two week low of $0.28 and a fifty-two week high of $1.70.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Soligenix in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, Soligenix currently has a consensus rating of “Sell”.

About Soligenix

Soligenix, Inc is a U.S.-based biopharmaceutical company focused on developing treatments for rare diseases and serious medical conditions with limited therapeutic options. The company’s programs are primarily aimed at immunology, inflammation, infectious diseases and oncology, with an emphasis on advancing candidates through clinical development and regulatory approval.

Soligenix’s pipeline has included SGX301, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma; SGX942, an innate defense regulator investigated for inflammatory conditions such as oral mucositis; and SGX945, a related candidate studied for Behçet’s disease.